K
COMPANY PROFILE
Kings Biotech
Valuation
$250–500M
Last recorded · 2021
Total funding
$10–50M
Disclosed equity funding
At a glance
- Status
- Operational
- Headquarters
- China
- Open positions
- None listed
- Dealroom signal
- 12.1/100
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Dec 2021 | $47M | $188M | China Everbright Investment Management · HSG · Pan-Lin Asset Management · GF Qianhe | ↗ |
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
0 profiles shownExplore the complete relationship graph →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
China Everbright Investment Management
HSG
Pan-Lin Asset Management
GF Qianhe
Founders
Hidden — book a demo/100
quality score
Key operators
Hidden — book a demo
quality score
Potential founders
Hidden — book a demo
likely future founders
Startup mafia
Hidden — book a demo
alumni-founded startups
Talent movements
Hidden — book a demo in · Hidden — book a demo out
past 12 months
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kings Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kings Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.